Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

However, if the FDA removes a drug from its shortage list, these compounded versions are no longer allowed to be sold. Compounded drugs are not approved by the FDA. Why Did the FDA Change Its Stance?

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was ...

The US Food and Drug Administration ... approved by the FDA, and it is expected to become available in the first half of 2025. Stelara, manufactured by Johnson & Johnson, has a list price of ...

While many people think attaining healthy weight loss is as easy as eating a balanced diet and engaging in regular physical ...

If there's a diet ... drugs are in short supply enabled thousands, or even millions, of people to access costly GLP-1 ...

“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s division ... wouldn’t pay the list price. The approval of Cobenfy ...

2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with ... COPD-related changes in the lungs. Dupixent’s list of indications already include asthma, eczema ...

the next step will be for the FDA to propose adding bemotrizinol to the list of over-the-counter drugs that are "generally recognized as safe and effective" to be sold to Americans. The public ...